Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Veracyte Inc VCYT

Healthcare Biotechnology
Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory... see more

Recent & Breaking News (NDAQ:VCYT)

Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022

Business Wire July 14, 2022

New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte's Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis

Business Wire July 13, 2022

Veracyte Named a San Francisco "Bay Area Top Workplace" For Ninth Consecutive Year

Business Wire June 27, 2022

New Data Show Strong Performance of Veracyte's Afirma GSC in Real-World Clinical Practice

Business Wire June 20, 2022

Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte's Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression

Business Wire June 3, 2022

Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer

Business Wire May 31, 2022

 New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier

Business Wire May 26, 2022

Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay's Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors

Business Wire May 26, 2022

Veracyte to Present at Upcoming Investor Conferences

Business Wire May 26, 2022

Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test's Clinical Performance and Utility in Lung Cancer Risk Assessment

Business Wire May 16, 2022

Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer

Business Wire May 12, 2022

Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting

Business Wire May 12, 2022

Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022

Business Wire May 4, 2022

Veracyte Announces First Quarter 2022 Financial Results

Business Wire May 3, 2022

Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis

Business Wire May 2, 2022

Intellia Therapeutics Names Muna Bhanji, R.Ph., to its Board of Directors

GlobeNewswire May 2, 2022

Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference

Business Wire April 28, 2022

Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference

Business Wire April 26, 2022

Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022

Business Wire April 19, 2022

Veracyte to Participate in the Cowen 42nd Annual Health Care Conference

Business Wire March 1, 2022